Free Newsletter
Sanofi to plow $6B into vaccines
If anyone harbors doubts that vaccines are hot properties in today's pharma world, an announcement from Sanofi-Aventis should take care of them. Sanofi says it expects global vaccine sales to double to $34 billion by 2016, and so it plans to invest some $6 billion to expand its production capacity to meet that huge increase in demand. The company will be adding onto current plants and building new ones, at 15 manufacturing sites in all.
Partially driving that mushrooming demand is another big growth area for pharma: the developing world. Sanofi's vaccines CEO says economic growth in emerging markets will goose vaccine demand because as people earn more, they're more likely to seek out immunizations for themselves and their children.
- see the Wall Street Journal story
- get the news from AFX
Related Articles:
Sanofi files new vaccine tech
Booming vaccine market swells Sanofi's revenue
Vaccine "renaissance" attracts huge new venture investments
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: